Rethinking the use of oral agents in the treatment of type 2 diabetes mellitus

Research output: Contribution to journalArticle

Abstract

Objective: To present an approach to the management of type 2 diabetes mellitus, focusing on the optimal incorporation of newer oral antidiabetic agents into the management plan. Data Sources: A MEDLINE search (January 1990-December 1997) was conducted for English-language clinical study reports, abstracts, and review articles pertaining to the pathophysiology and management of type 2 diabetes. Reference lists from the publications were searched for other original articles, and other sources were reviewed. Data Extraction: The majority of clinical studies synthesized in this article were double-blind studies. Data and recommendations of the American Diabetes Association and other authoritative groups were also included. Data Synthesis: Impaired pancreatic insulin secretion; resistance of peripheral tissues, particularly skeletal muscle, to the action of insulin; increased hepatic production of glucose; and excessive food intake contribute to hyperglycemia in type 2 diabetes. Oral antidiabetic agents that permit an attack on all four factors are now available. Controlling the blood glucose concentration helps to reduce the morbidity and mortality associated with the microvascular, neurologic, and macrovascular complications of diabetes. Conclusions: Therapeutic agents that target the specific pathophysiologic aspects of type 2 diabetes are now available. These newer agents can be used alone or in combination with each other, older agents, or insulin. This expanded armamentarium should help to improve glycemic control in many patients and to reduce the mortality and morbidity due to this disease.

Original languageEnglish (US)
Pages (from-to)146-152
Number of pages7
JournalJournal of Pharmacy Technology
Volume14
Issue number4
StatePublished - Jul 1998

Fingerprint

Type 2 Diabetes Mellitus
Insulin
Hypoglycemic Agents
Morbidity
Mortality
Information Storage and Retrieval
Diabetes Complications
Therapeutics
Double-Blind Method
MEDLINE
Hyperglycemia
Vascular Resistance
Nervous System
Blood Glucose
Publications
Skeletal Muscle
Language
Eating
Glucose
Liver

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Rethinking the use of oral agents in the treatment of type 2 diabetes mellitus. / Raskin, Philip.

In: Journal of Pharmacy Technology, Vol. 14, No. 4, 07.1998, p. 146-152.

Research output: Contribution to journalArticle

@article{3667a01dbdf9414383201dfd970cc9ae,
title = "Rethinking the use of oral agents in the treatment of type 2 diabetes mellitus",
abstract = "Objective: To present an approach to the management of type 2 diabetes mellitus, focusing on the optimal incorporation of newer oral antidiabetic agents into the management plan. Data Sources: A MEDLINE search (January 1990-December 1997) was conducted for English-language clinical study reports, abstracts, and review articles pertaining to the pathophysiology and management of type 2 diabetes. Reference lists from the publications were searched for other original articles, and other sources were reviewed. Data Extraction: The majority of clinical studies synthesized in this article were double-blind studies. Data and recommendations of the American Diabetes Association and other authoritative groups were also included. Data Synthesis: Impaired pancreatic insulin secretion; resistance of peripheral tissues, particularly skeletal muscle, to the action of insulin; increased hepatic production of glucose; and excessive food intake contribute to hyperglycemia in type 2 diabetes. Oral antidiabetic agents that permit an attack on all four factors are now available. Controlling the blood glucose concentration helps to reduce the morbidity and mortality associated with the microvascular, neurologic, and macrovascular complications of diabetes. Conclusions: Therapeutic agents that target the specific pathophysiologic aspects of type 2 diabetes are now available. These newer agents can be used alone or in combination with each other, older agents, or insulin. This expanded armamentarium should help to improve glycemic control in many patients and to reduce the mortality and morbidity due to this disease.",
author = "Philip Raskin",
year = "1998",
month = "7",
language = "English (US)",
volume = "14",
pages = "146--152",
journal = "Journal of Pharmacy Technology",
issn = "8755-1225",
publisher = "Harvey Whitney Books Company",
number = "4",

}

TY - JOUR

T1 - Rethinking the use of oral agents in the treatment of type 2 diabetes mellitus

AU - Raskin, Philip

PY - 1998/7

Y1 - 1998/7

N2 - Objective: To present an approach to the management of type 2 diabetes mellitus, focusing on the optimal incorporation of newer oral antidiabetic agents into the management plan. Data Sources: A MEDLINE search (January 1990-December 1997) was conducted for English-language clinical study reports, abstracts, and review articles pertaining to the pathophysiology and management of type 2 diabetes. Reference lists from the publications were searched for other original articles, and other sources were reviewed. Data Extraction: The majority of clinical studies synthesized in this article were double-blind studies. Data and recommendations of the American Diabetes Association and other authoritative groups were also included. Data Synthesis: Impaired pancreatic insulin secretion; resistance of peripheral tissues, particularly skeletal muscle, to the action of insulin; increased hepatic production of glucose; and excessive food intake contribute to hyperglycemia in type 2 diabetes. Oral antidiabetic agents that permit an attack on all four factors are now available. Controlling the blood glucose concentration helps to reduce the morbidity and mortality associated with the microvascular, neurologic, and macrovascular complications of diabetes. Conclusions: Therapeutic agents that target the specific pathophysiologic aspects of type 2 diabetes are now available. These newer agents can be used alone or in combination with each other, older agents, or insulin. This expanded armamentarium should help to improve glycemic control in many patients and to reduce the mortality and morbidity due to this disease.

AB - Objective: To present an approach to the management of type 2 diabetes mellitus, focusing on the optimal incorporation of newer oral antidiabetic agents into the management plan. Data Sources: A MEDLINE search (January 1990-December 1997) was conducted for English-language clinical study reports, abstracts, and review articles pertaining to the pathophysiology and management of type 2 diabetes. Reference lists from the publications were searched for other original articles, and other sources were reviewed. Data Extraction: The majority of clinical studies synthesized in this article were double-blind studies. Data and recommendations of the American Diabetes Association and other authoritative groups were also included. Data Synthesis: Impaired pancreatic insulin secretion; resistance of peripheral tissues, particularly skeletal muscle, to the action of insulin; increased hepatic production of glucose; and excessive food intake contribute to hyperglycemia in type 2 diabetes. Oral antidiabetic agents that permit an attack on all four factors are now available. Controlling the blood glucose concentration helps to reduce the morbidity and mortality associated with the microvascular, neurologic, and macrovascular complications of diabetes. Conclusions: Therapeutic agents that target the specific pathophysiologic aspects of type 2 diabetes are now available. These newer agents can be used alone or in combination with each other, older agents, or insulin. This expanded armamentarium should help to improve glycemic control in many patients and to reduce the mortality and morbidity due to this disease.

UR - http://www.scopus.com/inward/record.url?scp=0031654548&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031654548&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031654548

VL - 14

SP - 146

EP - 152

JO - Journal of Pharmacy Technology

JF - Journal of Pharmacy Technology

SN - 8755-1225

IS - 4

ER -